SCHEMBL2050348

SCHEMBL2050348

NC(=O)Cc1c([C@H]2CCOC2)c(C(N)=O)cc2c3c([nH]c12)CCCC3

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.46
ALDH1A1 P00352 3/20 0.46
MAPT P10636 3/20 0.46
ALOX15 P16050 2/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
IKBKB O14920 1/20 0.46
USP2 O75604 1/20 0.46
TP53 P04637 1/20 0.46
MAPK10 P53779 1/20 0.46
CASP1 P29466 2/20 0.42
CASP7 P55210 2/20 0.42
BTK Q06187 6/20 0.41
GFER P55789 1/20 0.34
KDM4E B2RXH2 2/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2044387 1.00 HSD17B10 (0.46) HSD17B10ALDH1A1MAPTALOX15MAPK1
SCHEMBL2044381 0.93 HSD17B10 (0.47) HSD17B10ALDH1A1MAPTALOX15MAPK1
SCHEMBL4094487 0.68 SMN1; SMN2 (0.41) HSD17B10ALDH1A1MAPTALOX15MAPK1
SCHEMBL2021582 0.65 SMN1; SMN2 (0.45) HSD17B10ALDH1A1MAPTALOX15MAPK1
SCHEMBL4094478 0.65 MAPT (0.42) HSD17B10ALDH1A1MAPTALOX15MAPK1
SCHEMBL30159841 0.63 MAPT (0.69) HSD17B10ALDH1A1MAPTALOX15MAPK1
SCHEMBL2021575 0.63 MAPT (0.43) HSD17B10ALDH1A1MAPTALOX15MAPK1
SCHEMBL30159934 0.61 MAPT (0.67) HSD17B10ALDH1A1MAPTALOX15MAPK1
SCHEMBL19715437 0.61 BTK (0.64) HSD17B10ALDH1A1MAPTALOX15MAPK1
SCHEMBL150478 0.61 ALOX15 (1.00) HSD17B10ALDH1A1MAPTALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160180-A1 Cannabinoid Receptor Ligands ASTRAZENECA AB (SE) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160180-A1 Cannabinoid Receptor Ligands CNR1, CNR2, OPRL1 HSD17B10 3976/4885ALDH1A1 2240/4885MAPT 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.